1,721,513 research outputs found
Recent advances in understanding frontotemporal degeneration
No full textFrontotemporal degeneration (FTD) is a heterogeneous spectrum of neurodegenerative disorders characterized by diverse clinical presentations, neuropathological characteristics, and underlying genetic causes. In the last few years, several advances in the knowledge of clinical and biological aspects have been accomplished and three major scenarios have emerged that will represent the core issues in the FTD scene over the next few years. Foremost, the development of cerebrospinal fluid and blood biomarkers as well as neuroimaging techniques will aid the pursuit of new diagnostic and prognostic markers able to identify the ongoing proteinopathy and predict disease progression, which is key in identifying and stratifying patients for enrolment in clinical trials as well as evaluating response to treatment. On the other hand, current research has focused on the first attempts to slow down or revert disease progression, with the identification of disease modulators associated with disease onset and the ongoing development of the first pharmacological treatments for both sporadic and genetic FTD. Future research will certainly improve our knowledge of FTD and possibly open up a new era of disease-modifying therapies for this still-orphan disorder
Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration
Full text linkMarcello Giunta,1 Eino Solje,2 Fabrizio Gardoni,3 Barbara Borroni,1 Alberto Benussi1 1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 2Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland; 3Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, ItalyCorrespondence: Alberto BenussiClinica Neurologica, Università degli Studi di Brescia, P.le Spedali Civili, 1, Brescia 25100, ItalyTel +39 0303995632Email [email protected]: Frontotemporal dementia is a clinically, genetically and pathologically heterogeneous neurodegenerative disorder, enclosing a wide range of different pathological entities, associated with the accumulation of proteins such as tau and TPD-43. Characterized by a high hereditability, mutations in three main genes, MAPT, GRN and C9orf72, can drive the neurodegenerative process. The connection between different genes and proteinopathies through specific mechanisms has shed light on the pathophysiology of the disease, leading to the identification of potential pharmacological targets. New experimental strategies are emerging, in both preclinical and clinical settings, which focus on small molecules rather than gene therapy. In this review, we provide an insight into the aberrant mechanisms leading to FTLD-related proteinopathies and discuss recent therapies with the potential to ameliorate neurodegeneration and disease progression.Keywords: frontotemporal dementia, frontotemporal lobar degeneration, therapy, TDP-43, tau, C9orf72, GRN, MAP
Clinical and biological phenotypes of frontotemporal dementia: Perspectives for disease modifying therapies
No full textFrontotemporal Dementia (FTD) is a progressive neurodegenerative condition which encompasses a group of clinically, neuropathologically and genetically heterogeneous disorders characterized by selective involvement of the frontal and temporal lobes. FTD is characterized by changes in behaviour and personality, frontal executive deficits and language dysfunction. Different phenotypes have been defined on the basis of presenting clinical symptoms, behavioural variants of FTD (bvFTD) and primary progressive aphasia (PPA), which includes nonfluent/agrammatic variant PPA (avPPA) and semantic variant PPA (svPPA). These presentations can overlap with atypical parkinsonian disorders (i.e., corticobasal syndrome, progressive supranuclear palsy) and amyotrophic lateral sclerosis. Each syndrome can be associated with one or more neuropathological hallmark, and in some cases it may be due to autosomal inherited disorder caused by mutations in a number of genes. Currently, there is no specific treatment available to prevent disease progression. FTD treatment is based on symptomatic management, and most therapies lack quality evidence from randomized, placebo-controlled clinical trials. Recent advances in the understanding of FTD pathophysiology and genetics have led to the development of potentially disease-modifying therapies. In this review, we discussed current knowledge and recommendations with regards to symptomatic and disease-modifying therapies
Multimodal face and voice recognition disorders in a case with unilateral right anterior temporal lobe atrophy
No full textObjective: Familiar face recognition disorders are often observed in patients with lesions of the right anterior temporal lobe (ATL). It is not clear, however, if this defect must be considered as a form of associative prosopagnosia, or as a multimodal (face and voice) people recognition disorder, because voice recognition is rarely examined in these patients. The most appropriate manner of solving this problem could consist in evaluating, in one or more patients with right ATL lesions, recognition disorders through face and voice of the same well known people. Methods: The 'Famous People Recognition Battery' (FPRB), in which the same 40 persons (very well-known at the national level) should be identified through face and voice recognition, was used to clarify this issue. The FPRB was administered to a 56-year-old woman (BM) who complained, as early sign of a fronto-temporal degeneration, of familiar people recognition defects in a context of relatively intact cognitive functions. Results: On the FPRB, BM showed a severe defect of people recognition (familiarity judgement) and identification through face and voice, but not through personal name. Voxel-based morphometry showed a focal atrophy of the right ATL (temporo-polar cortex and anterior parts of perirhinal and entorhinal cortices). Conclusions: the present case report seems to show that a unilateral right ATL atrophy can lead to a multimodal people recognition disorder through face and voice, in the absence of recognition difficulties through personal name
The role of the motor system in action naming in patients with neurodegenerative extrapyramidal syndromes.
No full textLegal issues in frontotemporal dementia: aspects still neglected in court and clinical practice
No full text- …
